MindBio Therapeutics - Marktführer bei Mircodosing LSD
eröffnet am 12.06.23 09:59:53 von
neuester Beitrag 07.03.24 09:45:28 von
neuester Beitrag 07.03.24 09:45:28 von
Beiträge: 17
ID: 1.369.728
ID: 1.369.728
Aufrufe heute: 0
Gesamt: 985
Gesamt: 985
Aktive User: 0
ISIN: CA60256C1086 · WKN: A3EB9V · Symbol: MBIO
0,0550
CAD
-8,33 %
-0,0050 CAD
Letzter Kurs 03.05.24 CSE
Neuigkeiten
02.05.24 · Accesswire  |
01.05.24 · Accesswire |
30.04.24 · Accesswire |
23.04.24 · Accesswire |
16.04.24 · Accesswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 13,110 | +38,44 | |
| 6,5000 | +27,45 | |
| 1,2100 | +21,00 | |
| 48,25 | +19,94 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 24,050 | -12,55 | |
| 4,0300 | -12,96 | |
| 6,2600 | -14,25 | |
| 3,8500 | -14,45 | |
| 36,70 | -22,87 |
Beitrag zu dieser Diskussion schreiben
FeedbackChartbild top
Bereitet grade einen weiteren Ausbruch richtung 10 bis 15 Cent vor Der CEO Justin Hanka liefert und liefert
Kurs hat sich schön stabilisiert bei 6 Cent in Kanada.
Weitere News
Genehmigung erhalten, wird also spannend die Tage/Wochen.
https://www.stockwatch.com/News/Item/Z-C!MBIO-3520367/C/MBIO
Genehmigung erhalten, wird also spannend die Tage/Wochen.
https://www.stockwatch.com/News/Item/Z-C!MBIO-3520367/C/MBIO
Ist ein langer Weg.
Aber könnte vom Tief seine 1000% machen.
Dyor
Aber könnte vom Tief seine 1000% machen.
Dyor
Trading Spotlight
Ergebnisse der 2a Studie - in "coming weeks"
Bis dahin sollte die Spannung und der Kurs weiter steigen.Bei überragenden Resultaten dürfte Kurs nach oben keine Grenzen kennen.
Immerhin erste Anwendung, welche Behandlung von Depressionen während des "normalen" Alltags zu Hause ermöglicht.
Menschen können weiter zur Arbeit etc., und müssen sich nicht in stätionäre Behandlung begeben.
Dürfte auch für die Arbeitgeberwelt interessant werden
2a Studie abgeschlossen - news vom 14.2.
VANCOUVER, BC / ACCESSWIRE / February 14, 2024 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), a leading biopharma company in psychiatric medicine development, is delighted to announce the completion of its landmark Phase 2a clinical trial in patients with Major Depressive Disorder.MindBio has achieved a significant milestone becoming the only organisation in the world to have completed a Phase 2a clinical trial with regulatory approvals for take-home use and handling of a psychedelic medicine by trial patients, specifically a proprietary titratable form of Lysergic Acid Diethylamide (LSD) in microdoses called MB22001 has been specifically designed for take home use.
MindBio's Phase 2a clinical trial in patients with Major Depressive Disorder is an open label trial that looked for clinically significant changes in depression rating scores using a global standard for measuring the severity of depression, the MADRS (Montgomery Asberg Depression Rating Scale). MB22001 was administered in titratable microdoses to clinical trial participants. Now that the trial has been completed, the primary end point for assessing the success of MB22001 for the treatment of depression is an improvement in the MADRS.
Chief Executive Officer and Co-founder of MindBio Justin Hanka said "This is a pivotal moment for MindBio as we progress the development of novel treatments for psychiatric conditions. Our scientific team is processing the vast amount of data from the clinical trial, and we look forward to announcing the results of this important clinical trial expected to be presented in the coming weeks".
Concurrently, MindBio is also conducting a Phase 2B trial in late-stage cancer patients experiencing existential distress, a common phenomenon experienced at end of life, a mix of depressive, anxiety and distress symptoms that often is treated with anti-depressants.
The completion of MindBio's landmark Phase 2a Depression trial comes after the successful completion of its extensive Phase 1 trial in 80 healthy individuals which yielded positive safety and tolerance data as well as statistically significant improvements in mood marked by increases in "energy", "wellness" "happiness", "creativity" "social connectivity" and a reduction in "anger" and "irritability". We also made a new discovery from sleep data in healthy individuals. We found that MB22001 produced statistically significant improvements in sleep, including REM sleep time, total sleep time and total quality of sleep observed the day after each dose day.
Kanda SK gestern 8 Cent
Aufwärtsbewegung setzt sich fort.Keine Pumperei hier, schön Schritt für Schritt
Auszug aus kanadischen Forum ceo.ca
this is very tightly held now and an extreme game changing catalyst within weeks .... I have been talking to people in the industry and they agree at home dosing is the future for mental health treatment especially in depression .... you get up you dose and you move on with your day functioning in society instead of locking yourself inside your room not being able to face the world .... already having regulatory approval is huge and the value about to be realized from current trial data will be incredible from this not looked at yet company .... the doctors , scientists and other board members on this team from Ausie and New Zealand are top of the line .... Strategy accumulate accumulate accumulate before the boom Wochenschluss in Kanada 4,5 cent
Bid ask 4,5 zu 5.Sehr schöne Basis
Nächste Woche weiter up
Durchsuchen
